Cardiac technology company HeartBeam Inc (NASDAQ:BEAT) said on Tuesday that it has acquired substantially all assets of LIVMOR, a digital health solutions company that provides a patient-engaging remote monitoring system of critical physiological biomarkers.

This acquisition extends HeartBeam's operations in remote monitoring and detection with full ownership of the Halo+ Atrial Fibrillation (AF) Detection System, a prescription wearable for continuous cardiac rhythm monitoring which is cleared by the US Food and Drug Administration (FDA).

Financial terms of the deal were not disclosed.

In February 2022, HeartBeam partnered with LIVMOR to build a HeartBeam-branded version of LIVMOR's Halo cloud-based software platform to connect physicians and patients. With the Halo cloud-based platform, HeartBeam was able to meet its schedule for FDA submission of the HeartBeam AIMI software for acute care settings that provides a 3D vector electrogram (VECG) comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack.

Under the terms of the acquisition agreement, HeartBeam purchased three issued US patents, LIVMOR's technology, including the Halo AF Detection System, its business contracts and relationships, as well as all Samsung watch and tablet inventory. HeartBeam also hired LIVMOR's key technical employees.